Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Accounts Payables (2022 - 2025)

Oramed Pharmaceuticals' Accounts Payables history spans 4 years, with the latest figure at $6.2 million for Q4 2025.

  • For Q4 2025, Accounts Payables changed N/A year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, changed N/A, while the annual FY2025 figure was $6.2 million, N/A changed from the prior year.
  • Accounts Payables reached $6.2 million in Q4 2025 per ORMP's latest filing, up from $560000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.2 million in Q4 2025 to a low of $560000.0 in Q3 2025.
  • Average Accounts Payables over 4 years is $3.2 million, with a median of $3.5 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: surged 320.65% in 2024, then crashed 88.79% in 2025.
  • A 4-year view of Accounts Payables shows it stood at $4.2 million in 2022, then crashed by 61.3% to $1.6 million in 2023, then soared by 210.44% to $5.0 million in 2024, then increased by 24.14% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Accounts Payables are $6.2 million (Q4 2025), $560000.0 (Q3 2025), and $2.2 million (Q2 2025).